Catalent
CTLT
#1590
Rank
HK$84.16 B
Marketcap
HK$463.69
Share price
0.98%
Change (1 day)
49.03%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

Revenue for Catalent (CTLT)

Revenue in 2024 (TTM): HK$34.25 Billion

According to Catalent's latest financial reports the company's current revenue (TTM ) is HK$34.09 Billion. In 2023 the company made a revenue of HK$32.00 Billion a decrease over the revenue in the year 2022 that were of HK$37.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Catalent from 2013 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) HK$34.25 B7.02%
2023 HK$32.00 B-13.89%
2022 HK$37.16 B6.32%
2021 HK$34.95 B30.14%
2020 HK$26.86 B26.38%
2019 HK$21.25 B9.1%
2018 HK$19.48 B8.44%
2017 HK$17.96 B22.2%
2016 HK$14.70 B3.4%
2015 HK$14.21 B-0.73%
2014 HK$14.32 B2.22%
2013 HK$14.01 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
HK$4.90 B-85.62%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$1.66 B-95.12%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$30.42 B-10.75%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
HK$2.47 B-92.75%๐Ÿ‡บ๐Ÿ‡ธ USA